Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727373020.793562618 ◽

2019 ◽

Author(s):

Corrado Girmenia

Keyword(s):

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727373020.793538186 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30051-1 ◽

2016 ◽

Vol 17 (7) ◽

pp. 928-942 ◽

Cited By ~ 285

Author(s):

Barbara Eichhorst ◽

Anna-Maria Fink ◽

Jasmin Bahlo ◽

Raymonde Busch ◽

Gabor Kovacs ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

First Line ◽

Open Label ◽

Phase 3

Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30168-0 ◽

2017 ◽

Vol 4 (11) ◽

pp. e534-e543 ◽

Cited By ~ 20

Author(s):

Asher A Chanan-Khan ◽

Andrey Zaritskey ◽

Miklos Egyed ◽

Samuel Vokurka ◽

Sergey Semochkin ◽

...

Keyword(s):

Maintenance Therapy ◽

Lymphocytic Leukaemia ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726009690.793538184 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Lymphocytic Leukaemia ◽

Small Lymphocytic Lymphoma ◽

Phase 3 ◽

Double Blind ◽

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70242-x ◽

2011 ◽

Vol 12 (13) ◽

pp. 1204-1213 ◽

Cited By ~ 64

Author(s):

Thomas Elter ◽

Liana Gercheva-Kyuchukova ◽

Halyna Pylylpenko ◽

Tadesuz Robak ◽

Branimir Jaksic ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Phase 3 ◽

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)00143-6 ◽

2015 ◽

Vol 16 (13) ◽

pp. 1370-1379 ◽

Cited By ~ 72

Author(s):

Marinus H J van Oers ◽

Kazimierz Kuliczkowski ◽

Lukáš Smolej ◽

Mario Petrini ◽

Fritz Offner ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Open Label ◽

Phase 3

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study

The Lancet Haematology ◽

10.1016/s2352-3026(17)30235-1 ◽

2018 ◽

Vol 5 (2) ◽

pp. e82-e94 ◽

Cited By ~ 10

Author(s):

Caroline Dartigeas ◽

Eric Van Den Neste ◽

Julie Léger ◽

Hervé Maisonneuve ◽

Christian Berthou ◽

...

Keyword(s):

Elderly Patients ◽

Lymphocytic Leukaemia ◽

Open Label ◽

Phase 3 ◽

Rituximab Maintenance

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(10)61381-5 ◽

2010 ◽

Vol 376 (9747) ◽

pp. 1164-1174 ◽

Cited By ~ 1245

Author(s):

M Hallek ◽

K Fischer ◽

G Fingerle-Rowson ◽

AM Fink ◽

R Busch ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30443-5 ◽

2020 ◽

Vol 21 (9) ◽

pp. 1188-1200 ◽

Cited By ~ 7

Author(s):

Othman Al-Sawaf ◽

Can Zhang ◽

Maneesh Tandon ◽

Arijit Sinha ◽

Anna-Maria Fink ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Open Label ◽

Phase 3